Table of Content

1 Report Overview
1.1 Neisseria meningitidis Infections Drug Definition
1.2 Market by Type
1.2.1 Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 MGBBP-3
1.2.3 NCL-195
1.2.4 TP-10
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Neisseria meningitidis Infections Drug Sales
2.1 Global Neisseria meningitidis Infections Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Neisseria meningitidis Infections Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Neisseria meningitidis Infections Drug Revenue by Region
2.3.1 Global Neisseria meningitidis Infections Drug Revenue by Region (2018-2023)
2.3.2 Global Neisseria meningitidis Infections Drug Revenue by Region (2024-2034)
2.4 Global Neisseria meningitidis Infections Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Neisseria meningitidis Infections Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Neisseria meningitidis Infections Drug Sales Quantity by Region
2.6.1 Global Neisseria meningitidis Infections Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Neisseria meningitidis Infections Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Neisseria meningitidis Infections Drug Sales Quantity by Manufacturers
3.1.1 Global Neisseria meningitidis Infections Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Neisseria meningitidis Infections Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Neisseria meningitidis Infections Drug Sales in 2024
3.2 Global Neisseria meningitidis Infections Drug Revenue by Manufacturers
3.2.1 Global Neisseria meningitidis Infections Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Neisseria meningitidis Infections Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Neisseria meningitidis Infections Drug Revenue in 2024
3.3 Global Neisseria meningitidis Infections Drug Sales Price by Manufacturers
3.4 Global Key Players of Neisseria meningitidis Infections Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neisseria meningitidis Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Product Offered and Application
3.8 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Neisseria meningitidis Infections Drug Sales Quantity by Type
4.1.1 Global Neisseria meningitidis Infections Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Neisseria meningitidis Infections Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Neisseria meningitidis Infections Drug Revenue by Type
4.2.1 Global Neisseria meningitidis Infections Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Neisseria meningitidis Infections Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
4.3 Global Neisseria meningitidis Infections Drug Price by Type
4.3.1 Global Neisseria meningitidis Infections Drug Price by Type (2018-2023)
4.3.2 Global Neisseria meningitidis Infections Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Neisseria meningitidis Infections Drug Sales Quantity by Application
5.1.1 Global Neisseria meningitidis Infections Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Neisseria meningitidis Infections Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Neisseria meningitidis Infections Drug Revenue by Application
5.2.1 Global Neisseria meningitidis Infections Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Neisseria meningitidis Infections Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
5.3 Global Neisseria meningitidis Infections Drug Price by Application
5.3.1 Global Neisseria meningitidis Infections Drug Price by Application (2018-2023)
5.3.2 Global Neisseria meningitidis Infections Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Neisseria meningitidis Infections Drug Sales by Company
6.1.1 North America Neisseria meningitidis Infections Drug Revenue by Company (2018-2023)
6.1.2 North America Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023)
6.2 North America Neisseria meningitidis Infections Drug Market Size by Type
6.2.1 North America Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Neisseria meningitidis Infections Drug Revenue by Type (2018-2034)
6.3 North America Neisseria meningitidis Infections Drug Market Size by Application
6.3.1 North America Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Neisseria meningitidis Infections Drug Revenue by Application (2018-2034)
6.4 North America Neisseria meningitidis Infections Drug Market Size by Country
6.4.1 North America Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Neisseria meningitidis Infections Drug Revenue by Country (2018-2034)
6.4.3 North America Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neisseria meningitidis Infections Drug Sales by Company
7.1.1 Europe Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Neisseria meningitidis Infections Drug Revenue by Company (2018-2023)
7.2 Europe Neisseria meningitidis Infections Drug Market Size by Type
7.2.1 Europe Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Neisseria meningitidis Infections Drug Revenue by Type (2018-2034)
7.3 Europe Neisseria meningitidis Infections Drug Market Size by Application
7.3.1 Europe Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Neisseria meningitidis Infections Drug Revenue by Application (2018-2034)
7.4 Europe Neisseria meningitidis Infections Drug Market Size by Country
7.4.1 Europe Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Neisseria meningitidis Infections Drug Revenue by Country (2018-2034)
7.4.3 Europe Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Neisseria meningitidis Infections Drug Sales by Company
8.1.1 China Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023)
8.1.2 China Neisseria meningitidis Infections Drug Revenue by Company (2018-2023)
8.2 China Neisseria meningitidis Infections Drug Market Size by Type
8.2.1 China Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2034)
8.2.2 China Neisseria meningitidis Infections Drug Revenue by Type (2018-2034)
8.3 China Neisseria meningitidis Infections Drug Market Size by Application
8.3.1 China Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2034)
8.3.2 China Neisseria meningitidis Infections Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Neisseria meningitidis Infections Drug Sales by Company
9.1.1 APAC Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Neisseria meningitidis Infections Drug Revenue by Company (2018-2023)
9.2 APAC Neisseria meningitidis Infections Drug Market Size by Type
9.2.1 APAC Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Neisseria meningitidis Infections Drug Revenue by Type (2018-2034)
9.3 APAC Neisseria meningitidis Infections Drug Market Size by Application
9.3.1 APAC Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Neisseria meningitidis Infections Drug Revenue by Application (2018-2034)
9.4 APAC Neisseria meningitidis Infections Drug Market Size by Region
9.4.1 APAC Neisseria meningitidis Infections Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Neisseria meningitidis Infections Drug Revenue by Region (2018-2034)
9.4.3 APAC Neisseria meningitidis Infections Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Beijing Minhai Biotechnology Co Ltd
11.1.1 Beijing Minhai Biotechnology Co Ltd Company Information
11.1.2 Beijing Minhai Biotechnology Co Ltd Overview
11.1.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Products and Services
11.1.5 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug SWOT Analysis
11.1.6 Beijing Minhai Biotechnology Co Ltd Recent Developments
11.2 Biological E Ltd
11.2.1 Biological E Ltd Company Information
11.2.2 Biological E Ltd Overview
11.2.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Biological E Ltd Neisseria meningitidis Infections Drug Products and Services
11.2.5 Biological E Ltd Neisseria meningitidis Infections Drug SWOT Analysis
11.2.6 Biological E Ltd Recent Developments
11.3 China National Pharmaceutical Group Corp
11.3.1 China National Pharmaceutical Group Corp Company Information
11.3.2 China National Pharmaceutical Group Corp Overview
11.3.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Products and Services
11.3.5 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug SWOT Analysis
11.3.6 China National Pharmaceutical Group Corp Recent Developments
11.4 GlaxoSmithKline Plc
11.4.1 GlaxoSmithKline Plc Company Information
11.4.2 GlaxoSmithKline Plc Overview
11.4.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Products and Services
11.4.5 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug SWOT Analysis
11.4.6 GlaxoSmithKline Plc Recent Developments
11.5 Griffith University
11.5.1 Griffith University Company Information
11.5.2 Griffith University Overview
11.5.3 Griffith University Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Griffith University Neisseria meningitidis Infections Drug Products and Services
11.5.5 Griffith University Neisseria meningitidis Infections Drug SWOT Analysis
11.5.6 Griffith University Recent Developments
11.6 ImmunoBiology Ltd
11.6.1 ImmunoBiology Ltd Company Information
11.6.2 ImmunoBiology Ltd Overview
11.6.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Products and Services
11.6.5 ImmunoBiology Ltd Neisseria meningitidis Infections Drug SWOT Analysis
11.6.6 ImmunoBiology Ltd Recent Developments
11.7 JN-International Medical Corp
11.7.1 JN-International Medical Corp Company Information
11.7.2 JN-International Medical Corp Overview
11.7.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Products and Services
11.7.5 JN-International Medical Corp Neisseria meningitidis Infections Drug SWOT Analysis
11.7.6 JN-International Medical Corp Recent Developments
11.8 MGB Biopharma Ltd
11.8.1 MGB Biopharma Ltd Company Information
11.8.2 MGB Biopharma Ltd Overview
11.8.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Products and Services
11.8.5 MGB Biopharma Ltd Neisseria meningitidis Infections Drug SWOT Analysis
11.8.6 MGB Biopharma Ltd Recent Developments
11.9 Panacea Biotec Ltd
11.9.1 Panacea Biotec Ltd Company Information
11.9.2 Panacea Biotec Ltd Overview
11.9.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Products and Services
11.9.5 Panacea Biotec Ltd Neisseria meningitidis Infections Drug SWOT Analysis
11.9.6 Panacea Biotec Ltd Recent Developments
11.10 Pfizer Inc
11.10.1 Pfizer Inc Company Information
11.10.2 Pfizer Inc Overview
11.10.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Pfizer Inc Neisseria meningitidis Infections Drug Products and Services
11.10.5 Pfizer Inc Neisseria meningitidis Infections Drug SWOT Analysis
11.10.6 Pfizer Inc Recent Developments
11.11 Sanofi Pasteur SA
11.11.1 Sanofi Pasteur SA Company Information
11.11.2 Sanofi Pasteur SA Overview
11.11.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Products and Services
11.11.5 Sanofi Pasteur SA Recent Developments
11.12 Serum Institute of India Ltd
11.12.1 Serum Institute of India Ltd Company Information
11.12.2 Serum Institute of India Ltd Overview
11.12.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Products and Services
11.12.5 Serum Institute of India Ltd Recent Developments
11.13 Wellstat Vaccines LLC
11.13.1 Wellstat Vaccines LLC Company Information
11.13.2 Wellstat Vaccines LLC Overview
11.13.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Products and Services
11.13.5 Wellstat Vaccines LLC Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Neisseria meningitidis Infections Drug Value Chain Analysis
12.2 Neisseria meningitidis Infections Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neisseria meningitidis Infections Drug Production Mode & Process
12.4 Neisseria meningitidis Infections Drug Sales and Marketing
12.4.1 Neisseria meningitidis Infections Drug Sales Channels
12.4.2 Neisseria meningitidis Infections Drug Distributors
12.5 Neisseria meningitidis Infections Drug Customers
13 Market Dynamics
13.1 Neisseria meningitidis Infections Drug Industry Trends
13.2 Neisseria meningitidis Infections Drug Market Drivers
13.3 Neisseria meningitidis Infections Drug Market Challenges
13.4 Neisseria meningitidis Infections Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neisseria meningitidis Infections Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of MGBBP-3
Table 3. Major Manufacturers of NCL-195
Table 4. Major Manufacturers of TP-10
Table 5. Major Manufacturers of Others
Table 6. Global Neisseria meningitidis Infections Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Neisseria meningitidis Infections Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Neisseria meningitidis Infections Drug Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2018-2023)
Table 10. Global Neisseria meningitidis Infections Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Neisseria meningitidis Infections Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 13. Global Neisseria meningitidis Infections Drug Sales by Region (2018-2023) & (K Pcs)
Table 14. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2018-2023)
Table 15. Global Neisseria meningitidis Infections Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2024-2034)
Table 17. Global Neisseria meningitidis Infections Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 18. Global Neisseria meningitidis Infections Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 19. Global Neisseria meningitidis Infections Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global Neisseria meningitidis Infections Drug Revenue Share by Manufacturers (2018-2023)
Table 21. Global Neisseria meningitidis Infections Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 22. Global Key Players of Neisseria meningitidis Infections Drug, Industry Ranking, 2021 VS 2024
Table 23. Global Neisseria meningitidis Infections Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Neisseria meningitidis Infections Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neisseria meningitidis Infections Drug as of 2024)
Table 25. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 30. Global Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Neisseria meningitidis Infections Drug Sales Quantity Share by Type (2018-2023)
Table 32. Global Neisseria meningitidis Infections Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Neisseria meningitidis Infections Drug Revenue Share by Type (2018-2023)
Table 36. Global Neisseria meningitidis Infections Drug Revenue Share by Type (2024-2034)
Table 37. Neisseria meningitidis Infections Drug Price by Type (2018-2023) & (USD/Pcs)
Table 38. Global Neisseria meningitidis Infections Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 40. Global Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Neisseria meningitidis Infections Drug Sales Quantity Share by Application (2018-2023)
Table 42. Global Neisseria meningitidis Infections Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Neisseria meningitidis Infections Drug Revenue Share by Application (2018-2023)
Table 46. Global Neisseria meningitidis Infections Drug Revenue Share by Application (2024-2034)
Table 47. Neisseria meningitidis Infections Drug Price by Application (2018-2023) & (USD/Pcs)
Table 48. Global Neisseria meningitidis Infections Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Neisseria meningitidis Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 50. North America Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 51. North America Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 52. North America Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 54. North America Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 56. North America Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 58. North America Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 60. North America Neisseria meningitidis Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 61. North America Neisseria meningitidis Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 63. North America Neisseria meningitidis Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 65. Europe Neisseria meningitidis Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 66. Europe Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 67. Europe Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 69. Europe Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 71. Europe Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 73. Europe Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 75. Europe Neisseria meningitidis Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 76. Europe Neisseria meningitidis Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 78. Europe Neisseria meningitidis Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 80. China Neisseria meningitidis Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 81. China Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 82. China Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 84. China Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 86. China Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 88. China Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 90. APAC Neisseria meningitidis Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 91. APAC Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 92. APAC Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 94. APAC Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 96. APAC Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 98. APAC Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Neisseria meningitidis Infections Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 100. APAC Neisseria meningitidis Infections Drug Revenue by Region (2018-2023) & (US$ Million)
Table 101. APAC Neisseria meningitidis Infections Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Neisseria meningitidis Infections Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 103. APAC Neisseria meningitidis Infections Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 105. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 111. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 118. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Beijing Minhai Biotechnology Co Ltd Company Information
Table 120. Beijing Minhai Biotechnology Co Ltd Description and Overview
Table 121. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 122. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product and Services
Table 123. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug SWOT Analysis
Table 124. Beijing Minhai Biotechnology Co Ltd Recent Developments
Table 125. Biological E Ltd Company Information
Table 126. Biological E Ltd Description and Overview
Table 127. Biological E Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 128. Biological E Ltd Neisseria meningitidis Infections Drug Product and Services
Table 129. Biological E Ltd Neisseria meningitidis Infections Drug SWOT Analysis
Table 130. Biological E Ltd Recent Developments
Table 131. China National Pharmaceutical Group Corp Company Information
Table 132. China National Pharmaceutical Group Corp Description and Overview
Table 133. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 134. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product and Services
Table 135. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug SWOT Analysis
Table 136. China National Pharmaceutical Group Corp Recent Developments
Table 137. GlaxoSmithKline Plc Company Information
Table 138. GlaxoSmithKline Plc Description and Overview
Table 139. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 140. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product and Services
Table 141. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug SWOT Analysis
Table 142. GlaxoSmithKline Plc Recent Developments
Table 143. Griffith University Company Information
Table 144. Griffith University Description and Overview
Table 145. Griffith University Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 146. Griffith University Neisseria meningitidis Infections Drug Product and Services
Table 147. Griffith University Neisseria meningitidis Infections Drug SWOT Analysis
Table 148. Griffith University Recent Developments
Table 149. ImmunoBiology Ltd Company Information
Table 150. ImmunoBiology Ltd Description and Overview
Table 151. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 152. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product and Services
Table 153. ImmunoBiology Ltd Neisseria meningitidis Infections Drug SWOT Analysis
Table 154. ImmunoBiology Ltd Recent Developments
Table 155. JN-International Medical Corp Company Information
Table 156. JN-International Medical Corp Description and Overview
Table 157. JN-International Medical Corp Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 158. JN-International Medical Corp Neisseria meningitidis Infections Drug Product and Services
Table 159. JN-International Medical Corp Neisseria meningitidis Infections Drug SWOT Analysis
Table 160. JN-International Medical Corp Recent Developments
Table 161. MGB Biopharma Ltd Company Information
Table 162. MGB Biopharma Ltd Description and Overview
Table 163. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 164. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product and Services
Table 165. MGB Biopharma Ltd Neisseria meningitidis Infections Drug SWOT Analysis
Table 166. MGB Biopharma Ltd Recent Developments
Table 167. Panacea Biotec Ltd Company Information
Table 168. Panacea Biotec Ltd Description and Overview
Table 169. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 170. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product and Services
Table 171. Panacea Biotec Ltd Neisseria meningitidis Infections Drug SWOT Analysis
Table 172. Panacea Biotec Ltd Recent Developments
Table 173. Pfizer Inc Company Information
Table 174. Pfizer Inc Description and Overview
Table 175. Pfizer Inc Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 176. Pfizer Inc Neisseria meningitidis Infections Drug Product and Services
Table 177. Pfizer Inc Neisseria meningitidis Infections Drug SWOT Analysis
Table 178. Pfizer Inc Recent Developments
Table 179. Sanofi Pasteur SA Company Information
Table 180. Sanofi Pasteur SA Description and Overview
Table 181. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 182. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product and Services
Table 183. Sanofi Pasteur SA Recent Developments
Table 184. Serum Institute of India Ltd Company Information
Table 185. Serum Institute of India Ltd Description and Overview
Table 186. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 187. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product and Services
Table 188. Serum Institute of India Ltd Recent Developments
Table 189. Wellstat Vaccines LLC Company Information
Table 190. Wellstat Vaccines LLC Description and Overview
Table 191. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 192. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product and Services
Table 193. Wellstat Vaccines LLC Recent Developments
Table 194. Key Raw Materials Lists
Table 195. Raw Materials Key Suppliers Lists
Table 196. Neisseria meningitidis Infections Drug Distributors List
Table 197. Neisseria meningitidis Infections Drug Customers List
Table 198. Neisseria meningitidis Infections Drug Market Trends
Table 199. Neisseria meningitidis Infections Drug Market Drivers
Table 200. Neisseria meningitidis Infections Drug Market Challenges
Table 201. Neisseria meningitidis Infections Drug Market Restraints
Table 202. Research Programs/Design for This Report
Table 203. Key Data Information from Secondary Sources
Table 204. Key Data Information from Primary Sources
List of Figures
Figure 1. Neisseria meningitidis Infections Drug Product Picture
Figure 2. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Neisseria meningitidis Infections Drug Market Share by Type in 2024 & 2034
Figure 4. MGBBP-3 Product Picture
Figure 5. NCL-195 Product Picture
Figure 6. TP-10 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 9. Global Neisseria meningitidis Infections Drug Market Share by Application in 2024 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Neisseria meningitidis Infections Drug Report Years Considered
Figure 14. Global Neisseria meningitidis Infections Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Neisseria meningitidis Infections Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Neisseria meningitidis Infections Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Neisseria meningitidis Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Neisseria meningitidis Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Neisseria meningitidis Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Neisseria meningitidis Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Neisseria meningitidis Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Neisseria meningitidis Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Neisseria meningitidis Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Neisseria meningitidis Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Neisseria meningitidis Infections Drug Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Neisseria meningitidis Infections Drug Revenue in 2024
Figure 32. Neisseria meningitidis Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Neisseria meningitidis Infections Drug Revenue Market Share by Company in 2024
Figure 38. North America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Company in 2024
Figure 39. North America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Neisseria meningitidis Infections Drug Revenue Share by Country (2018-2034)
Figure 44. North America Neisseria meningitidis Infections Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Neisseria meningitidis Infections Drug Sales Quantity Market Share by Company in 2024
Figure 48. Europe Neisseria meningitidis Infections Drug Revenue Market Share by Company in 2024
Figure 49. Europe Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Neisseria meningitidis Infections Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Neisseria meningitidis Infections Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Neisseria meningitidis Infections Drug Sales Quantity Market Share by Company in 2024
Figure 61. China Neisseria meningitidis Infections Drug Revenue Market Share by Company in 2024
Figure 62. China Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Neisseria meningitidis Infections Drug Sales Quantity Market Share by Company in 2024
Figure 67. APAC Neisseria meningitidis Infections Drug Revenue Market Share by Company in 2024
Figure 68. APAC Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Neisseria meningitidis Infections Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Neisseria meningitidis Infections Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Neisseria meningitidis Infections Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Neisseria meningitidis Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Neisseria meningitidis Infections Drug Value Chain
Figure 93. Neisseria meningitidis Infections Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed